Operating profit margin also seen higher.
Leading pharma reports robust Q1 results.
The rating is 'Overweight'.
Annual General Meeting to be held on 26 April.
There are only a handful of women in senior roles.
Magyar Telekom and OTP are the top picks.
'Buy' rating remains.
Profit doubled, yet share price is falling.
Analysts expect major profit growth for Q416.
Levosert goes to Europe.
In female healthcare product acquistions.
Finally exceeding 2007 level.
Negotiating the curves of the biosimilar scene.
The rating is 'Buy'.